Since the beginning of his second term, President Trump has introduced a series of initiatives aimed at addressing the high costs associated with prescription medications in the United States.
This focus on drug pricing comes as a response to growing concerns among the American public. A recent poll conducted by KFF revealed that approximately 60% of adults in the U.S. are anxious about their ability to afford prescription medications for themselves or their families. Furthermore, over 80% of respondents deemed current drug prices as excessive, with a majority advocating for increased regulation to help reduce costs. Notably, Americans are paying roughly three times more than individuals in other countries for identical medications.
In July, Trump reached out to 17 pharmaceutical companies, urging them to voluntarily reduce their drug prices. Following that, he claimed to have negotiated directly with numerous pharmaceutical executives at the White House. By December, he announced that he successfully secured a “most favored nation” pricing model for Medicaid, which provides health coverage for low-income Americans.
The launch of TrumpRx, a platform designed to assist cash-paying patients in locating discounted medications, was another significant development. Additionally, he promised to expedite the availability of biosimilar products—generic alternatives to certain high-cost specialty drugs—by streamlining the regulatory processes involved with the FDA.
However, the actual impact of these initiatives remains unclear, as many aspects of the negotiations, including specifics about which drugs would be included, are not well-defined. White House spokesperson Kush Desai did not respond to inquiries regarding TrumpRx.
Medicaid already procures drugs at substantial discounts, and many patients might find better alternatives through commercial discount programs or their insurance plans, which often include copayment cards from drug manufacturers. Consequently, the number of Americans who will genuinely benefit from these new initiatives appears limited, although some individuals may experience advantages.
Mark Cuban, a billionaire investor actively working to reduce drug prices, stated, “If it makes a difference to any patient, it’s a win.” He highlighted discounted pricing on TrumpRx for branded fertility drugs and GLP-1 weight loss medications for those without insurance or coverage. In 2022, Cuban founded the Mark Cuban Cost Plus Drug Co. (Cost Plus Drugs) to offer medications at lower prices by removing intermediaries and selling directly to consumers. The majority of the drugs he provides are generics.
Aaron Kesselheim, a Harvard Medical School professor specializing in drug pricing, criticized the announcements made by Trump, describing them as “one-off agreements made for publicity purposes” that do not fundamentally alter drug pricing structures. He further noted that these agreements lack transparency and are not enforceable.
Questions remain about which specific drugs would be available at “most favored nation” prices and how those prices would be determined. Evidence suggests that not all drugs are included in this pricing model.
According to 46brooklyn, a consulting firm monitoring brand-name drug prices, nearly 1,000 brand-name drugs saw price increases in January 2026, marking the highest number of price hikes in a single year. For instance, Pfizer raised the list prices of 71 drugs by an average of 5% in the first week of 2026, while reducing the price of only one drug by 9.8%.
One of the most significant benefits for patients has likely come from the Trump administration’s continuation of a program initiated by the Biden administration, which allows Medicare to negotiate prices for high-cost drugs. The negotiated reductions for the first ten drugs—ranging from blood thinners to insulins—took effect on January 1. With discounts exceeding 50% for certain products, this initiative is projected to save Medicare around $6 billion annually and limit out-of-pocket expenses for Medicare patients on Part D prescription drugs to $2,000 starting in 2025.
Moreover, 15 additional high-cost drugs, including popular weight loss and cancer medications, are set for negotiation in 2025, with the new prices coming into effect the following year. Another 15 drugs are scheduled for negotiation this year, leading to an anticipated total savings of over $20 billion annually for Medicare.
Despite these developments, drug industry lobbyists have been active in trying to mitigate the effects of these changes, with some successes. For example, the One Big Beautiful Bill Act has exempted drugs for rare diseases from negotiations.
Kesselheim remarked on the historic nature of these negotiations, noting, “This is the first time the United States has negotiated prices, similar to other developed nations,” while also observing that innovation in the pharmaceutical sector has not ceased.
It’s important to note that these discounts primarily benefit Medicare recipients. While the Trump administration’s recent initiatives may assist some additional patients, their overall effectiveness is limited and often requires awareness of how to access these savings.
Trump’s public engagements with leading pharmaceutical executives have led to agreements, but the tangible benefits for patients remain questionable. After a meeting with Pfizer CEO Albert Bourla, the company announced discounts on over 30 drugs, with Bourla describing the arrangement as “a win for American patients, a win for American leadership, and a win for Pfizer.”
The discounts are available through TrumpRx, which also provides co-branded coupons on GoodRx.com, a platform that already offers discounts for numerous medications.
Pfizer has capitalized on the agreement, framing it as part of a broader, landmark most favored nation agreement with the U.S. government. A Pfizer spokesperson highlighted a press release from September, indicating that the TrumpRx.gov platform offers potential savings for patients that can reach as high as 85%.
Most of the drugs listed are brand-name products, competing against significantly cheaper generic alternatives from various manufacturers, such as the cholesterol-lowering medication Colestid.
